Introduction
Edge-to-edge mitral valve repair by MitraClip (Abbott, Abbott Park, IL, USA) implantation is the most widely used percutaneous treatment option for patients with prohibitive surgical risk and severe, symptomatic mitral regurgitation (MR). Compared to conventional mitral valve surgery, MitraClip implantation features inferior efficacy in reducing MR. 1 However, beyond long-term MR 4 and quality of life. 4 In patients with severe MR, the rate of heart failure rehospitalization is known to drop by 48-73% 1 year after MitraClip demonstrated a significant reduction in cardiac rehospitalizations after MitraClip compared to a control group on optimal medical therapy. 7 Nonetheless, rehospitalization still occurs frequently after MitraClip implantation. In large registries and trials, 1-year rehospitalization rates are around 20-41%.
2 -6 The identification of patients at high risk for readmission due to decompensated heart failure is essential to effectively allocate resources targeting the prevention of heart failure rehospitalization. Therefore, we aimed to identify independent predictors for rehospitalization after MitraClip implantation in prohibitive surgical risk patients undergoing MitraClip implantation for symptomatic, severe MR at our centre.
Methods

Study population
We evaluated 355 consecutive patients with high-grade MR who underwent MitraClip implantation between January 2010 and December 2016 for their baseline and procedural characteristics, peri-procedural outcome and clinical endpoints.
All patients suffered from symptomatic high-grade MR (i.e. grade III or IV) documented by echocardiography. 8 Pre-procedural transoesophageal and transthoracic echocardiography (TTE) and invasive haemodynamic measurement by cardiac catheterization were performed prior to MitraClip implantation procedure. Risk factors for surgical repair of the mitral valve were evaluated prospectively using the Society of Thoracic Surgeons (STS, http://riskcalc.sts.org/ stswebriskcalc/#/calculate) model for mortality and the European System for Cardiac Operative Risk Evaluation (EuroSCORE II, http:// www.euroscore.org/calc.html). MitraClip implantation was performed in a hybrid catheterization lab in general anaesthesia. MitraClip was implanted under fluoroscopic and echocardiographic guidance via venous access through transatrial route.
No exclusion criteria existed for the participation in our prospective MiTra ULM registry. The interdisciplinary heart team made decision for transcatheter edge-to-edge mitral valve repair by MitraClip in accordance with current guidelines on valvular heart disease. 9, 10 Prior to MitraClip implantation, all patients provided written informed consent for retrospective and prospective data collection. The study complied with the principles of the 1975 Declaration of Helsinki and local regulations. The local ethics committee approved the research protocol.
Baseline, procedural and post-procedural characteristics
All baseline procedural and post-procedural data (symptoms, electrocardiograms, echocardiography, cardiac catheterization, blood testing) were prospectively recorded. High-sensitive troponin T and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were analysed by electrochemical luminescent immunoassay (Cobas 8000; Elecsys Troponin T-hs STAT assay; Roche Diagnostics GmbH, Mannheim, Germany).
Procedural success was defined as successful delivery of the MitraClip device and effective reduction in MR of more than two degrees. Peri-procedural adverse events were recorded, including in-hospital death, post-procedural myocardial infarction, major bleeding according to Mitral Valve Academic Research Consortium (MVARC) ≥2,
cardiogenic shock, peri-procedural cardiopulmonary resuscitation, and stroke.
Mitral regurgitation assessment and measurement of mean transmitral pressure gradients by TTE were performed intra-procedurally and 1 day after MitraClip implantation. Intra-procedural and post-procedural TTE was performed by cardiologists specialized in non-invasive imaging according to current recommendations of the European Society of Cardiology. 8 Clinical follow-up/outcome Follow-up was conducted by routine clinical visit or phone contact after MitraClip implantation up to 3 years. Mean follow-up was 494.6 days. Only one patient was lost to follow-up. Rehospitalization for decompensated heart failure was defined as any readmission to our or any other hospital at least once due to pulmonary congestion and respiratory insufficiency, worsening oedema as well as hypoperfusion requiring inpatient treatment and optimization of heart failure therapy (diuretic/inotropic/mechanical).
Statistical analysis
Pre-procedural parameters, procedural data and post-procedural outcomes were compared between patients with and without rehospitalization for decompensated heart failure.
Normally distributed continuous variables were expressed as mean ± standard deviation and were compared with Student's t-test. Categorical variables are presented as frequencies and percentages. Differences between proportions were calculated using Chi 2 test. McNemar test was used to compare annual rate of rehospitalization before and after MitraClip implantation.
Univariate Cox proportional hazards regression analysis included all significant or probable risk factors (P < 0.1 in Student's t-test and Chi 2 test). Receiver-operating characteristic (ROC) analysis was performed for all significant variables of univariate analysis. Youden's index was used to select the optimal criterion (cut-off value) for the prediction of rehospitalization. Pearson's and Spearman Rho correlation function was used to analyse the association between troponin T, left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVESD), creatinine, NYHA class, EuroSCORE II, pre-existing implantable cardioverter-defibrillator (ICD), and functional MR. No relevant correlation was observed (r < 0.4) except for LVEF and LVESD (r = 0.78 and r = 0.80, respectively; P < 0.0001). Furthermore, we tested multi-collinearity and found the greatest variance inflation factors for LVEF and LVESD (3.0 and 2.8, respectively) indicating collinearity. Hence LVESD was not included in multivariate regression analysis due to clinical relation, significant correlation and collinearity with LVEF. 12 Multivariate Cox proportional hazards regression (full-model) analysis for 1-year rehospitalization and mortality was performed for all significant (P < 0.05) and probable (P < 0.20) influential variables of univariate analysis 12 : creatinine at baseline, EuroSCORE II, functional MR, pre-existing ICD, LVEF, NYHA functional class, and troponin T at baseline. For functional MR, a separate multivariate Cox regression analysis was performed, including troponin T, creatinine, EuroSCORE II, LVEF and NYHA functional class. For degenerative MR, multivariate regression analysis included troponin T and history of coronary artery disease.
Time-to-event analyses were performed using Kaplan-Meier estimates and were compared with the log-rank test. Kaplan-Meier curves were generated for time to rehospitalization. Association of 1-year 
Results
Between January 2010 and December 2016, 355 consecutive patients at increased surgical risk with high-grade MR (i.e. grade III or IV) underwent transcatheter edge-to-edge mitral valve repair by MitraClip implantation at our MiTra Ulm centre. Within the first year after MitraClip, 64 patients (18.0%) were readmitted to hospital for decompensated heart failure (rehospitalization group). The mean duration until rehospitalization was 117 days (median 76 days, interquartile range 39-156 days) after MitraClip implantation. A total of 291 patients did not require rehospitalization for heart failure in the first year after Mitra-Clip implantation (no rehospitalization group). In our cohort, the rate of rehospitalization for decompensated heart failure in the year prior to MitraClip was 52.7% (n = 187). By MitraClip, the rate of rehospitalization was reduced by 65.8% (absolute difference of 34.7%, 95% CI 28.2-41.1%; P < 0.0001).
Baseline characteristics of both patient groups are displayed in Table 1 . No statistical significant differences were observed between patients with and without rehospitalization after MitraClip implantation regarding co-morbidities and past cardiac history.
. Before MitraClip implantation, patients in the rehospitalization group had higher levels of troponin T (108.9 ± 324.3 vs. 42.9 ± 51.6 ng/L; P < 0.005) and higher levels of creatinine (146.4 ± 50.1 vs. 127.2 ± 71.0 mol/L; P = 0.04). The operative risk estimated by EuroSCORE II was higher in the rehospitalization group (10.6 ± 8.3 vs. 8 .3 ± 7.9, P = 0.037). Overall, 29.7% of the rehospitalized patients had a prior ICD implantation compared to 15.5% of not rehospitalized patients (P = 0.011).
Pre-procedural echocardiography ( Table 2 ) revealed a more severe reduction of LVEF in the rehospitalization group (36.1 ± 17.3% vs. 45.4 ± 17.3%; P < 0.001) compared to patients that were not hospitalized for heart failure within the first year after MitraClip. The aetiology of MR was mainly functional (73.0% vs. 48.9%; P < 0.001), and thus LVESD (50.5 ± 12.7 mm vs. 45.7 ± 14.2 mm; P = 0.039) and LVEDD (63.5 ± 10.1 mm vs. 60.9 ± 11.7 mm; P = 0.17) were consistently higher in the rehospitalization group. Invasive haemodynamic measurements of pulmonary pressures did not differ between groups ( Table 2) . Mean pulmonary artery pressure (32.5 ± 10.8 mmHg), systolic pulmonary artery pressure (49.9 ± 15.1 mmHg) and pulmonary capillary wedge pressure (22.0 ± 9.2 mmHg) indicated moderate pulmonary hypertension of the population. Baseline and pre-procedural characteristics for functional and degenerative aetiology of MR are displayed separately in the online supplementary Tables S1 and S2. In patients with functional MR requiring rehospitalization for decompensated heart failure after MitraClip, troponin T and EuroSCORE II were also significantly higher, and LVEF was markedly decreased. Compared to this, in patients with degenerative MR, history of coronary artery disease was more frequent in patients requiring rehospitalization within 1 year after MitraClip. Procedural characteristics were equivalent in the rehospitalization and no rehospitalization groups. MitraClip implantation was successful in 98.4% and 97.9%, respectively ( Table 3) . Intra-procedural and post-procedural echocardiography showed similar results regarding grade of MR and transvalvular mitral gradient in both groups. Rates of peri-procedural adverse events (i.e. in-hospital death, post-procedural myocardial infarction, major MVARC bleeding ≥2, cardiogenic shock, peri-procedural cardiopulmonary resuscitation and stroke) were comparable . Table 3) . Regarding post-procedural residual and short-term recurrence of MR, there were no significant differences between groups (1.45 ± 0.88 in the rehospitalization group and 1.40 ± 0.87 in the no rehospitalization group; P = 0.70). By univariate Cox proportional hazards regression analysis, baseline troponin T (P = 0.002), baseline LVEF (P < 0.001), EuroSCORE II (P = 0.027), baseline creatinine (P = 0.032) and functional MR (P = 0.001) were significant risk factors for rehospitalization during the first year after MitraClip implantation Figure 1 Rates of rehospitalization according to the presence or absence of risk factors. Baseline troponin T, pre-procedural left ventricular ejection fraction (LVEF), pre-operative EuroSCORE II, baseline creatinine and functional mitral regurgitation (MR) (all P < 0.001) were significant predictors for rehospitalization during the first year after MitraClip implantation (P-values by Chi 2 test). By receiver-operating characteristic analysis, troponin T >21 ng/L [sensitivity 87.2%, specificity 38.0%, area under the curve (AUC) 0.65, P < 0.001], LVEF ≤44% (sensitivity 72.1%, specificity 51.0%, AUC 0.65, P < 0.001), EuroSCORE II >6.1 (sensitivity 72.1%, specificity 51.0%, AUC 0.61, P = 0.003), creatinine >123 mol/L (sensitivity 67.7%, specificity 52.6%, AUC 0.65, P < 0.001), and New York Heart Association (NYHA) class IV (sensitivity 35.4%, specificity 70.8%, AUC 0.54, P = 0.27) were found to be optimal predictive criteria for rehospitalization. BNP, B-type natriuretic peptide; ICD, implantable cardioverter-defibrillator.
( Figure 1) . NYHA class (P = 0.10) and pre-existing ICD (P = 0.17) were classified as probable risk factors (P < 0.2). In our cohort, pulmonary pressures and high-grade tricuspid regurgitation did not predict rehospitalization.
In the search for independent predictors of rehospitalization after MitraClip procedure, we performed multivariate Cox proportional hazards regression analysis of all significant and probable risk factors: multivariate regression confirmed LVEF (P = 0.020), troponin T (P = 0.003) and NYHA class (P = 0.020) as independent predictors for rehospitalization within 1 year after MitraClip implantation after adjustment for creatinine, EuroSCORE II, pre-existing ICD and functional aetiology of MR.
The risk for rehospitalization after MitraClip implantation increased by 1.8-fold with each NYHA category (95% CI 1.1-2.9, P = 0.020) (Table 4, Figure 2C) .
By ROC analysis, the optimal predictive value of baseline troponin T for heart failure rehospitalization after MitraClip was >21 ng/L [sensitivity 87.2%, specificity 38.0%; area under the curve (AUC) 0.65, P < 0.001]. Conversely, if baseline troponin T was >21 ng/L, hazard ratio for heart failure rehospitalization was 5.1 (95% CI 2.8-9.2, P = 0.0001) (Figure 2A) .
The optimal predictive criterion of baseline LVEF was ≤44% (sensitivity 72.1%, specificity 51.0%, AUC 0.65, P < 0.001). If the LVEF was ≤44% before MitraClip implantation, hazard ratio for 1-year rehospitalization after MitraClip implantation was 2.5 (95% CI 1.5-4.2, P = 0.0009) ( Figure 2B) baseline LVEF (P = 0.002) and troponin T (P = 0.006) are independent predictors of 1-year rehospitalization ( Table 5) . NYHA class closely misses to be a predictor for rehospitalization in patients after Mitra-Clip with functional MR (P = 0.051). Compared to this, in patients with degenerative MR, only baseline troponin T (P = 0.025) predicts rehospitalization after MitraClip ( Table 6) . During 6-month-follow-up after MitraClip, persistency or recurrence of high-grade MR is associated with a 2.1-fold (95% CI 1.0-4.5, P = 0.041) risk of 1-year rehospitalization. Moreover, patients of the rehospitalization group had significantly increased Table 7) . During long-term follow-up over 3 years, odds ratio for all-cause mortality was 2.3 (confidence interval 1.3-4.1, P = 0.004) in the rehospitalization group compared to the no rehospitalization group. Correspondingly, odds ratio for cardiovascular mortality was 3.3 (95% CI 1.7-6.1, P = 0.0003) in patients requiring rehospitalization for decompensated heart failure, compared to the no rehospitalization group.
Discussion
MitraClip has emerged as a feasible and safe treatment option for patients with severe, symptomatic MR at prohibitive surgical risk.
Beneficial effects on reduction of MR, NYHA functional class, and quality of life have been documented in several trials. The MitraClip has proven to reduce the rate of rehospitalization 5 by 73% 1 year after the implantation procedure. 4 This significant decrease in rehospitalization rate for heart failure after MitraClip compared to optimal medical therapy not only improves quality of life but also ensures cost-effectiveness of the MitraClip procedure. 13 However, in this critically ill population with multiple cardiac and non-cardiac co-morbidities, rehospitalization occurs frequently after MitraClip implantation. Grasso et al. 14 demonstrated that two thirds of hospital readmissions occur for cardiovascular reasons (including heart failure, coronary artery disease and myocardial infarction, hypertension, arrhythmias, stroke, and peripheral artery disease), while anaemia and gastrointestinal bleeding are the most frequent non-cardiovascular causes of rehospitalization after MitraClip. After MitraClip implantation at our centre, rate of rehospitalization due to decompensated heart failure was 18.0%. In recent registries and trials, 1-year rates of heart failure rehospitalization differ widely from 18% to 41%. 2 -6 Hence, differences in patient characteristics might explain the variability of heart failure rehospitalization rates in different trials and registries. In this study, we aimed to identify predictors of readmission for decompensated heart failure to effectively allocate financial and medical resources targeting the prevention of heart failure rehospitalization and improvement of patients' clinical outcomes and quality of life.
In patients requiring rehospitalization, baseline troponin T and creatinine levels as well as preoperative EuroSCORE II were elevated. Furthermore, impaired LVEF and functional aetiology of MR were more frequent.
Functional MR is a common finding in heart failure patients with a high prevalence up to 50%. 15 In patients with acute heart failure receiving optimal medical treatment for decompensated heart failure, severity of functional MR correlates with adverse events comprising all-cause mortality and rehospitalization at 90 days after discharge from index hospitalization. 15 Regarding chronic heart failure, conflicting results exist on the prognostic significance of functional MR. 15 After MitraClip, Giannini et al. 7 showed in 60 patients with functional MR a significant reduction of rehospitalization rates, compared to patients on optimal medical therapy. However, in the multinational Transcatheter Valve Treatment (TCVT) Pilot Sentinel European Registry, 2 association of increased rates of rehospitalization in patients undergoing MitraClip for functional aetiology of MR has been observed. Nickenig et al. 2 found in their registry 1-year rehospitalization rates of 25 .8% in functional MR vs. 12.0% in degenerative MR after MitraClip implantation. Rudolph et al. 16 found no significant differences in rehospitalization rates at 6-month follow-up, but at 2-year follow-up after MitraClip implantation increased rehospitalization rates were linked to functional MR. Analogously, in our cohort, functional aetiology of MR was identified as a risk factor for 1-year rehospitalization (73.0% vs. 48.9%) after MitraClip by univariate analysis, but failed to predict rehospitalization for heart failure independently in multivariate analysis after adjustment for baseline troponin T, creatinine, EuroSCORE II, LVEF, NYHA class, and history of ICD implantation. NT-proBNP levels were higher in rehospitalized patients, in particular in the subgroup with functional MR, but did not reach statistical significance. NT-proBNP might not be an ideal risk predictor of clinical outcome in MitraClip patients. 17 This might explained by the secretion mechanism. Secretion of other peptides such as atrial natriuretic peptide (ANP) from atrial cardiomyocytes occurs immediately (by hormone secretion pattern) from secretory granules, whereas BNP is secreted belated from ventricular cardiomyocytes by gene expression. 18 Thus, in different cardiac pathologies with distinct pathophysiological stress pattern, ANP seems to be secreted in subclinical stages, whereas BNP is secreted during end-stage disease. Moreover, ANP rises significantly during cardiac hypertrophy as atrial pressures rise. In contrast, BNP increases when ventricular pressures rise at the end-stage of hypertrophy.
19 Accordingly, one pathophysiological hypothesis might be that atrial pressures are an essential mechanism in patients with severe MR, whereas ventricular pressures are more Figure 3 All-cause (A) and cardiovascular mortality (B) in the study groups at long-term follow-up.
important in end-stage heart failure patients with and without severe MR.
In our cohort, we identified baseline LVEF, troponin T and NYHA class as independent predictors for rehospitalization within the first year after MitraClip implantation by multivariate Cox proportional hazards regression analysis. Moreover, a combined endpoint of 1-year rehospitalization and mortality is also predicted by baseline LVEF, troponin T and NYHA class. Baseline creatinine levels, pre-operative EuroSCORE II, history of ICD implantation and functional aetiology of MR showed different distributions in the rehospitalization and no rehospitalization groups but failed to independently predict rehospitalization after MitraClip. In our study population, NYHA class at baseline was slightly higher in the rehospitalization group. Due to the prognostic impact . 21 and Puls et al. 5 found NYHA functional class IV to predict rehospitalization after MitraClip implantation. By contrast, Rudolph et al. 22 evaluated the 30-day clinical outcome of critically ill, not fully recompensated patients with severe MR undergoing MitraClip procedure. In these patients with NYHA class IV at the time point of MitraClip procedure, the rate of rehospitalization was comparable to patients 
P-value
Hazard ratio (95% CI) P-value Hazard ratio (95% CI) . Troponin T is well-established as a diagnostic biomarker for acute coronary syndrome and has been approved to predict cardiovascular events at long-term follow-up in healthy populations and stable coronary artery disease 17 as well as acute and chronic heart failure patients. 23, 24 Furthermore, in 34 MitraClip patients from our centre, it has been shown that troponin T is elevated in patients experiencing the combined endpoint of death or heart failure rehospitalization. 17 Similarly, in this study encompassing 355 patients, baseline troponin T was significantly elevated in patients requiring heart failure rehospitalization after MitraClip (108.9 vs. 42.9 ng/L). Moreover, by multivariate analysis, baseline troponin T was found to independently predict rehospitalization for decompensated heart failure in the total cohort of 355 patients, as well as in the subgroup of patients with either functional or degenerative MR. If baseline troponin T is >21 ng/L, hazard ratio for 1-year rehospitalization after MitraClip is 5.1.
The impact of severely impaired LVEF in patients undergoing MitraClip implantation has been assessed by Geis et al. 25 in the TRAMI registry. Patients with reduced left ventricular function benefit from MitraClip in terms of clinical symptoms and NYHA functional class after MitraClip. Still, increased 1-year mortality was associated with LVEF <30%. 25 Furthermore, in the GRASP-IT registry, all-cause rehospitalized patients had more often severely impaired left ventricular function.
14 In particular, the deterioration of left ventricular function after MitraClip was predictive of all-cause rehospitalization.
14 In our analysis of 355 patients receiving MitraClip, moderate to severe impairment of LVEF (≤44%) was an independent predictor of 1-year rehospitalization with a hazard ratio of 2. 5 . In particular, in patients with functional MR, LVEF predicts 1-year rehospitalization after MitraClip. Recurrent rehospitalizations for decompensated heart failure are common in heart failure patients. In large cohorts of heart failure patients with reduced ejection fraction, rehospitalization rate for decompensated heart failure was 61.3% in the first year after initial diagnosis. 26 Compared to this, in the subgroup of patients with severely reduced ejection fraction in our cohort, rehospitalization rate was 59% before Mitra-Clip implantation and was reduced by 52% in the first year after MitraClip implantation. In contrast, in the subgroup . of patients with normal to moderate impairment of LVEF, rate of 1-year rehospitalization for decompensated heart failure was reduced by 73% as described before by others. 4, 5 The impact of the presence and absence of the identified predictors (LVEF ≤44%, troponin T >21 ng/L, and NYHA class) on hospitalization rates in the year before and after MitraClip is summarized in Figure 4 .
Readmission for decompensated heart failure not only impacts negatively quality of life and cost-effectiveness of the MitraClip procedure, but is also associated with increased mortality in heart failure. 27 -29 In the ASCEND-HF trial, 29 rehospitalization correlated with all-cause mortality with a hazard ratio of 2.38. In our cohort of patients with severe MR, patients readmitted for decompensated heart failure after MitraClip implantation had a 2.3-fold increased risk for all-cause mortality and a 3.3-fold increased risk for cardiovascular mortality. Hence, baseline LVEF, troponin T and NYHA class are also independent predictors of the combined endpoint of 1-year rehospitalization and mortality after MitraClip. Despite the beneficial effects of MitraClip implantation on MR symptoms relief, improvement of NYHA functional class and quality of life in patients with symptomatic MR, the prognosis of these patients is predominantly driven by the severity of heart failure indicated by pre-procedural NYHA functional class, baseline troponin T levels and LVEF. The predictors for rehospitalization after MitraClip might identify those patients that remain at high risk for heart failure decompensation. This patient subgroup might benefit from closer ambulatory follow-up to optimize medical and device-based therapy in order to prevent rehospitalization and negative impact on quality of life.
Study limitations
This study was a single-centre trial with all of its inherent limitations: 355 consecutive patients were prospectively enrolled in this registry and retrospective data (past medical history) were collected. Multivariate Cox regression analysis was performed to identify independent predictors (baseline and procedural characteristics) for 1-year rehospitalization after MitraClip. Larger cohorts might enable the identification of additional predictors. Moreover, further validation of the identified predictors (troponin T, LVEF and NYHA class) in an external cohort might further enhance the significance of our findings.
Conclusion
After percutaneous edge-to-edge mitral valve repair by MitraClip implantation, 1-year rate of rehospitalization due to decompensated heart failure was 18.0%. Baseline LVEF beyond the cut-off of 44%, baseline troponin T >21 ng/L and pre-procedural NYHA class independently predict 1-year rehospitalization after MitraClip implantation and the combined endpoint of rehospitalization and mortality. Patients readmitted for decompensated heart failure after MitraClip implantation had a 2.3-fold increased risk for all-cause mortality and a 3.3-fold increased risk for cardiovascular mortality after MitraClip.
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Additional supporting information may be found online in the Supporting Information section at the end of the article. Table S1 . Baseline characteristics of patients with functional mitral regurgitation. Table S2 . Baseline characteristics of patients with degenerative mitral regurgitation.
Conflict of interest: none declared.
